Aurobindo Pharma Shares Surge on USFDA Approval for Liver Transplant Drug

• Aurobindo Pharma shares rose 2% after its subsidiary Eugia Pharma Specialities received USFDA approval for Everolimus Tablets.
• Everolimus Tablets, a generic version of Zortress, are indicated for organ rejection prophylaxis in kidney and liver transplant patients.
• The approval covers 0.25 mg, 0.5 mg, 0.75 mg, and 1 mg strengths, with launch expected in Q1 FY27.
• The approved product has an estimated market size of $78 million for the 12 months ended December 2025.
• This marks Eugia Pharma Specialities Group's 184th ANDA approval, including 10 tentative approvals.